A transitional assistance strategy, especially for a launch drug, includes: Clear definitions of short- and long-term success Robust, gross-to-net forecasts that account for both payer access and demand Plans and strategies to move patients from transitional assistance to coverage As IQVIA will explore in a forthcoming blog, Mounjaros launch transformed the GLP-1 market by driving demand for highly effective treatments that patients were largely able to acquire for free through transitional assistance
MicroRNA 146a is believed to interact with intracellular mediators such as interleukin 1 receptor-associated kinase 1 and mammal-affiliated tumor necrosis factor receptor-associated factor 6, both of which are involved in cytokine-related signal transduction
63-110 Clinicians may select one option first over another based on certain prominent presenting symptoms, for example, preferring low-dose naltrexone when pain is a prominent feature or guanfacine when hyperadrenergic orthostatic intolerance is a prominent feature
Low B12 levels can result in anemia, fatigue, brain fog, memory issues, and other neurological symptoms
Reduction in dark spots
